|
6 December 2004
Scottish Biomedical of Glasgow, UK and Sosei Co. Ltd. of Tokyo, Japan (4565, Tokyo Stock Exchange MOTHERS Index) have extended their research and development agreement. This latest investment is based on the success achieved during the initial collaboration and will further expand this preclinical research.
Dr Stephen Hammond, Chief Executive of Scottish Biomedical, commented, " We are delighted to continue and extend our established relationship with Sosei. The renewal reflects the success of this collaboration, and the ability of Scottish Biomedical to work with the global pharmaceutical industry to provide solutions for human disease challenges."
Dr Chizuko Koseki, Vice President of Research Planning and Head of DRP® added, Together with recent expansion of Soseis business, productivity of our Drug Reprofiling collaborations have become increasingly higher since we started several years ago. We are delighted to extend our agreement with Scottish Biomedical who possess the unique technologies and abilities to look for novel indications for our compounds.
Sosei Co. Ltd. founded in 1990 by Shinichi Tamura, the ex-CEO of Genentech Japan, is a public Japanese biopharmaceutical company with significant expertise in drug development. It enriches its core product pipeline by in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofiling Platform® (DRP®) and through new molecular entity (NME) research programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West. Sosei is also developing its own sales and marketing organization in Japan. The company is capitalising on its extensive global network established over the past 10 years in its successful technology transfer business. For further information about Sosei, please visit www.sosei.com.
Scottish Biomedical is a privately owned, Glasgow-based, contract research company providing pre-clinical drug discovery services to pharmaceutical and biotech companies.
With fully integrated biology and chemistry technology and expertise, the company is highly experienced in identifying new disease targets, developing primary and secondary assays, performing high throughput screening and identifying and optimising lead compounds. All of the intellectual property generated through Scottish Biomedicals drug discovery projects is owned by its clients. www.scottish-biomedical.com
For further information, please contact:
Neil McCahill, Marketing Manager, Scottish Biomedical
Tel: , Fax: , E-mail
Back to Latest News
|
